Aprotinin revisited

Abe DeAnda, Bruce D. Spiess

Research output: Contribution to journalEditorialpeer-review

10 Scopus citations


In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously brought up in similar studies—does aprotinin increase the risk of mortality and renal failure after cardiac surgery? Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results. The present review revisits the aprotinin controversy.

Original languageEnglish (US)
Pages (from-to)998-1002
Number of pages5
JournalJournal of Thoracic and Cardiovascular Surgery
Issue number5
StatePublished - Nov 2012
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Aprotinin revisited'. Together they form a unique fingerprint.

Cite this